April 3, 2024 BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non- hallucinogenic LSD-based Drug Candidate BETR-001
March 4, 2024 BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
January 2, 2024 BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
November 15, 2023 US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
September 12, 2023 BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
